depemokimab

Pharmaceutical

UK, US approve GSK’s twice-yearly asthma drug

DRRA2 weeks ago03 mins

Regulators in the UK and US are the first to approve GSK’s Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe asthma that has been billed as a major new product for the drugmaker. In the UK – the first market for the drug – the MHRA has cleared Exdensur (depemokimab) for the treatment of asthma…

Pharmaceutical

GSK closes on approval of asthma hope depemokimab

DRRA2 weeks ago03 mins

Among seven new medicines recommended for approval by the EMA’s human medicine advisory committee at its latest meeting is GSK’s depemokimab, a long-acting anti-IL-5 antibody for severe asthma and an inflammatory condition that causes nasal polyps. GSK hopes that depemokimab – which has the proposed trade name of Exdensur in the EU – will become…

BLOGGLE_TITLE – Skin Type Solutions

DMK Acne Treatment – Beautiful With Brains

Here’s Why the TRX Body Saw Is Such an Effective Exercise—And How to Do it Right

Does High-Fat Dairy Lower the Risk of Dementia?

Chris Bumstead Insists on No Rest Between Sets—and Why it’s Effective

How Physical Discomfort Affects Stress, Sleep, and Emotional Regulation

UK, US approve GSK’s twice-yearly asthma drug

GSK closes on approval of asthma hope depemokimab